GlassScriptPhysician profile
Goma Mayberry
NPI 1588101174
$3,413.84
in general payments reported to CMS, 2019-2025
26 companies · $555 in 2025
The $555 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $970 · 2022: $763 · 2023: $670 · 2024: $455 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $859.85 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $566.30 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $216.17 | 2021-2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.85 | 2021-2024 | Spiriva Respimat, Jardiance |
| Lilly USA, LLC | $173.93 | 2021-2023 | Mounjaro, Trulicity |
| Pfizer INC. | $171.27 | 2021-2025 | |
| Abbvie INC. | $164.92 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $153.77 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.25 | 2021-2024 | |
| Exact Sciences Corporation | $112.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.22 | 2021-2025 | Xifaxan |
| Amgen INC. | $88.33 | 2021-2024 | Prolia, Evenity, Otezla |
| Medtronic, INC. | $55.46 | 2024-2025 | Minimed 780g |
| Lundbeck LLC | $55.16 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $53.50 | 2021-2024 | Xarelto |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $47.01 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $42.18 | 2021-2023 | Ingrezza |
| Abbott Laboratories | $41.23 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $35.07 | 2022 | |
| Photonicare INC | $33.70 | 2023 | Otosight Middle Ear Scope |
| Astellas Pharma US INC | $30.46 | 2021-2023 | Myrbetriq |
| Vivus LLC | $22.17 | 2021 | |
| Esperion Therapeutics, INC. | $20.00 | 2021 | |
| Avanir Pharmaceuticals, INC. | $19.63 | 2021 | |
| Grt US Holding, INC. | $14.79 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Goma Mayberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.